RxDoctor Payments Data

Phyllis Zee, MD

Sleep Medicine · Chicago, ILNPI 1255418927

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $162,467 of the $214,168 with a category attached, or 75.9%. 10 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 34.8% of the total. Among sleep medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$214,168in general payments, 2019–2025

Across 126 payments — averaging $1699.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$74K
  • Eisai Inc.$36K
  • Eisai CO., LTD.$32K
  • Sanofi-aventis U.S. LLC$18K
  • Takeda Pharmaceuticals U.S.A., Inc.$16K
  • Idorsia Pharmaceuticals US Inc$14K
  • plus $23K from 4 others
$368,851in research payments, 2019–2025

Across 21 payments — averaging $17,564 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$297K
  • Vanda Pharmaceuticals Inc.$71K
  • Harmony Biosciences LLC$1K

What the payments were for

  • Consulting fees$162,46776%
  • Speaking & faculty fees$30,09114%
  • Travel & lodging$19,4599%
  • Food & beverage$2,1511%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$214,168 in reported general payments places this provider in the 95th percentile of 79 sleep medicine providers in Illinois.

See all sleep medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$6,175
Medicare patients
68
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant11$10,969
Methylphenidate ErMethylphenidate Hcl11$1,525
Pregabalin13$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckBelsomra$5,791$10,96911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 sleep medicine providers in Illinois.

Other sleep medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →